December 22, 2015
2 min read

Long-term free fatty acid reduction with acipimox improves fasting glucose levels

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Nondiabetic adults with insulin resistance and obesity saw improved fasting glucose levels and decreased free fatty acids after 6 months of treatment with the lipase inhibitor acipimox, according to research in The Journal of Clinical Endocrinology & Metabolism.

Hideo Makimura, MD, of the program in nutritional metabolism and neuroendocrine unit of Massachusetts General Hospital, and colleagues analyzed data from 39 healthy adults with obesity (BMI > 30 kg/m²) and a fasting plasma glucose between 100 mg/dL and 125 mg/dL randomly assigned acipimox 250 mg three times per day (n = 20; 65% men; 60% black; mean age, 47 years; mean BMI, 39.9 kg/m²) or matching placebo for 6 months (n = 18; 68.4% men; 52.6% white; mean age, 45 years; mean BMI, 38.9 kg/m²). Researchers measured insulin sensitivity, homeostatic model assessment of insulin resistance (HOMA-IR), lipid profile, adiponectin and mitochondrial function via the rate of phosphocreatine recovery after exercise on 31P-magnetic resonance spectroscopy, as well as muscle mitochondrial density and relevant muscle gene expression. FPG was measured at baseline and at 1-month intervals.

Fasting free fatty acid levels decreased in the acipimox group vs. placebo at 6 months (–0.29 mmol/L vs. 0.01 mmol/L; P = .02). Researchers found that fasting glucose decreased in adults assigned acipimox vs. placebo (effect size, –6 mg/dL; P = .02), and trends were seen for reduced fasting insulin (effect size, –6.8 µU/mL; P = .07) and HOMA-IR (effect size, –1.96; P = .06) and increased adiponectin (effect size, 668 ng/mL; P = .02).

The researchers did not observe effects on mitochondrial function, mitochondrial density or muscle insulin sensitivity, whereas previous short-term acipimox studies revealed improvements.

In addition, researchers did not observe changes in glucose uptake under hyperinsulinemic-euglycemic clamp conditions, also contradicting several short-term studies showing improved muscle insulin sensitivity.

“One potential explanation is that, although acipimox decreased fasting [free fatty acid] levels in our study, [free fatty acid] levels during the clamp did not differ between groups after suppression by insulin,” the researchers wrote. “Another potential explanation is that [intramyocellular lipid], rather than circulating lipid, may be the relevant determinant of muscle insulin sensitivity.” – by Regina Schaffer

Disclosure: Makimura became an employee of Merck after the study was completed and all data were collected. Please see the full study for the other authors’ relevant financial disclosures.